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Background: The aim of this study is to examine the associations between health utility (HU), health-related quality
of life (HRQoL), and patient characteristics in postmenopausal osteoporotic (PMO) women.
Methods: Baseline data from a subsample of 1,245 participants of the Multiple Outcomes of Raloxifene Evaluation
study, a randomized, placebo-controlled, multinational clinical trial to evaluate the safety and efficacy of raloxifene,
were analyzed. The study cohort included 694 participants from non-European Union (non-EU) countries and 551
participants from EU countries. All participants with complete baseline HU and HRQoL assessments were included
in the following analyses: 1) HU (HUI or EQ-5D) and HRQoL (QualEFFO or OPAQ and NHP) associations; 2) HU
variability explained by HRQoL domains; and 3) the percentage of HU variability explained by statistically significant
(p < 0.05) HRQoL domains, after adjusting for baseline characteristics.
Results: Several domains were significantly associated with HU scores. HU variance was well explained (41% to
61%) by 4 to 6 (p < 0.05) significant HRQoL domains. After controlling for baseline characteristics, 48% to 64% of the
HU variance was well explained by 5 to 7 significant (p < 0.05) HRQoL domains. Additional trend analyses detected
statistically significant decreases in HRQoL and HU scores with an increased number of vertebral and non-vertebral
fractures.
Conclusions: Both disease-targeted and generic HRQoL domains were well correlated with HU. A large percentage
(48% to 64%) of the HU variance was explained by HRQoL, after adjusting for baseline characteristics. Both disease-
targeted and generic HRQoL measures were significant predictors of HU. HRQoL and HU scores decreased with
increased vertebral and non-vertebral fractures.
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Osteoporosis is characterized by low bone mass and
micro-architectural deterioration of bone tissue, which
leads to increased bone fragility and risk of fracture. Osteo-
porosis is a major public health threat, affecting an esti-
mated 200 million postmenopausal osteoporotic (PMO)
women worldwide [1,2]. Osteoporosis influences multiple
dimensions of HRQoL [3-7]. Vertebral fractures in PMO
women can result in acute and chronic back pain, declines* Correspondence: rburge@lilly.com
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reproduction in any medium, provided the orin physical functioning, and psychosocial impairments
[8-14].
Previous research has reported that lumbar vertebral
fractures, in particular, are associated with a reduced
HRQoL, as measured by the Osteoporosis Assessment
Questionnaire (OPAQ) [9,15,16]; the European Union
(EU) Foundation of Osteoporosis Quality-of-Life Assess-
ment (QualEFFO) [7,16]; and, to a lesser degree, the
Nottingham Health Profile (NHP) and EQ-5D [11].
Fractures related to osteoporosis may also have an
impact on HU scores. HUs are measured on a scale of 0
to 1, with 0 being death and 1 being the best state oftd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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worse than death; however, values cannot rise above 1)
[17]. HU values provide preference-based measures of
utility that are used to derive quality-adjusted life years
(QALYs), which are standardized outcome measures
applicable to any therapeutic area, used in cost-utility
analyses (incremental costs divided by incremental
QALYs) in economic evaluations of competing health-
care interventions [18].
Marciniak et al. reported that in a group of women
initiating and continuing treatment with bone loss
medications, significantly lower EQ-5D (HU) scores
were associated with prior vertebral fractures, a fear of
falling, a number of ongoing comorbid conditions, a
higher body mass index (BMI), ongoing depression, and
initiating or switching treatments at baseline [19].
Although general measures of HRQoL have been widely
used in studies of osteoporosis, much less is known about
the relationship between disease-targeted HRQoL instru-
ments and preference-based HU instruments.
Recent research published by McDonough et al.
presented models that were developed to predict HU
(from estimates of EQ-5D [US version]) and the
SF-6D, which is a 6-dimensional health state classifi-
cation model created using the Medical Outcomes
Study Short Form (36) Health Survey (SF-36) [20].
Health state utility values (HSUVs/scores) for either
EQ-5D or SF-6D were generated using OPAQ data in
the models created [20]. This research provided a
first step in predicting HU scores (in this case EQ-
5D and the SF-6D HSUV estimates) using HRQoL
scores (in this research, the OPAQ disease-targeted
measure) when only HRQoL clinical trial data are
available [20].
The purpose of our study was to examine associations
between HRQoL, HU, and patient characteristics in
PMO women. In addition, we were interested in deter-
mining the potential for 2 disease-targeted, and 1 gen-
eric HRQoL/health status measure to predict HU in
PMO women with vertebral and non-vertebral fractures.
We hypothesized that the disease-targeted, generic, and
health status measures would correlate with 2 different
HU measures in PMO women, given the overlap in
some items within these instruments. Disease-targeted
instruments may study novel domains which may not be
reflected in a generic instrument, and could result in the
generic instrument being less sensitive to a specific
disease event and subsequent outcomes. Therefore, this
research may provide new evidence to support this
hypothesis, as well as new information to help better
characterize the associations between these classes of
instruments. The study also may provide new insights
on the underlying domain constructs for osteoporosis
HRQoL instruments.Methods
Data source
A subsample of 1,245 PMO women participating in the
Multiple Outcomes of Raloxifene Evaluation (MORE)
study, which was a randomized, placebo-controlled,
multinational clinical trial to evaluate the safety and effi-
cacy of raloxifene [21], was utilized as the data source.
Participants in MORE included 7,705 women who had
been PMO for at least 2 years and who were up to
80 years of age (mean age 66.5 years) with osteoporosis,
defined as low bone mineral density (BMD) or radio-
graphically apparent vertebral fractures [21]. The first
patient visit in the MORE study was in December 1994,
while the last patient visit occurred in September 1998.
The MORE study protocol was approved by the human
studies review board at each center, and informed con-
sent was obtained [21].
Study population
All participants with complete baseline HRQoL and HU
assessments were included in the analyses (all HRQoL
and HU assessments were administered at study baseline
and at months 12, 24, and 36). Of the original 7,705
MORE study subjects, 694 participants were from the
non-European Union (non-EU) countries of Australia
(n = 53), Canada (n = 110), New Zealand (n = 16), and the
United States (n = 515), and 551 subjects were from the EU
countries of Belgium (n = 38), United Kingdom (n = 141),
the Netherlands (n = 319), and Sweden (n = 53).
Major measurements
HRQoL measurements
For participants in the EU cohort, disease-targeted
HRQoL was assessed with the QualEFFO, a 54-item
instrument, which assesses 6 domains of HRQoL, includ-
ing pain, daily activity, mobility, general health, mental
health, and overall quality of life [8,11]. The instrument is
disease-targeted with response options on 5-point Likert
scales and visual analog scales (VASs). The QualEFFO
scores range from 0 to 100, with higher scores indicating
better HRQoL (higher scores: 100 = better for the original
54-item QualEFFO instrument used in this study) [8,11].
The additional items, which are not on the current Qua-
lEFFO instruments, were derived from questionnaires
used in the Mediterranean Osteoporosis Study and the
European Vertebral Osteoporosis Study [22]. The instru-
ment has been shown to have good test-retest reliability
(kappa 0.54 to 0.90) and internal consistency (Crohnbach’s
α 0.72 to 0.92) and demonstrates the ability to discrimin-
ate between women with vertebral fractures and without
fracture [23].
For subjects in the non-EU cohort, disease-targeted
HRQoL was assessed with the OPAQ, a 67-item instru-
ment that assesses HRQoL in 4 dimensions (physical
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tions) that cover the following 14 domains: walking/
bending, sitting/standing, dressing/reaching, household/
self-care, transfers, usual work, fear of falls, level of
tension, body image, independence, back pain, fatigue,
social activity, and support, family and friends. Response
options are based on a 4- to 5-point Likert scale, with a
variety of response options including all days, most days,
some days, few days, and no days [7,15,16]. The OPAQ
scores range from 0 to 100, with higher scores indicating
better HRQoL.
Generic HRQoL was assessed using the NHP for all
EU and non-EU participants. The NHP is a 38-item
instrument that provides a patient’s perception of HRQoL/
health status [24]. Response options on the NHP provide
dichotomous (Yes/No) indicators of emotional, social,
and physical health problems experienced by partici-
pants. There are 6 NHP domains, including emotional
reaction, energy, physical mobility, pain, sleep, and
social interaction [24]. Generic HRQoL scores range
from 0 to 100, with lower scores indicating lower levels of
distress [24].
HU measurements
For the non-EU cohort, HU was assessed using the Health
Utilities Index Mark 2 (HUI2), which is a preference-
based generic measure of utility that measures health
status. The HUI assesses a patient’s health in terms of abil-
ity or disability over the past 4 weeks [24]. There are 11
domains in the HUI, including reading, hearing, speaking,
emotions/happiness, pain/discomfort, walking, use of
hands/fingers, memory, cognition/problem solving, basic
care, and worry [25]. Scores on the HUI can range from 0
(value for being dead) to 1 (value for perfect health), with
higher HUI scores indicating better states of health.
For subjects in the EU cohort, HU was assessed using
the EQ-5D, which covers 5 dimensions of health [23]. Re-
spondents rate their current health state in the following 5
areas: mobility, self-care, usual activities, pain/discomfort,
and anxiety/depression. In addition, participants compare
their current health state to their health state last year at
this time and rate as better, same, or worse, and they also
provide VAS response options ranging from 0 (worst ima-
ginable health state) to 100 (best imaginable health state).
Statistical analyses
Subjects’ baseline demographic and clinical characteris-
tics were summarized for both cohorts. Mean and stand-
ard deviation (SD) were calculated for continuous
variables and proportions were reported for categorical
variables. T-tests on continuous variables and Fisher
exact tests on dichotomous variables were conducted to
test the baseline characteristics between the EU and
non-EU cohorts.Correlations between HU scores and HRQoL domain
scores were then conducted by using Pearson’s correl-
ation. For the non-EU cohort, this correlation included
assessment of OPAQ versus HUI and NHP versus HUI.
For the EU cohort, this included assessment of Qua-
lEFFO versus EQ-5D and NHP versus EQ-5D. In order
to derive the best independent determinants of HU and
to identify any redundant HRQoL domains within a
questionnaire, multiple stepwise regressions were con-
ducted using HU as a dependent variable and HRQoL
domain scores as independent variables. These analyses,
which examined the percentage of HU variance ex-
plained by HRQoL domains, were conducted separately
for the disease-targeted and generic HRQoL measures.
Multiple regressions, which used HU as a dependent
variable and baseline characteristics as independent vari-
ables, were conducted to identify significant baseline
characteristics (Table 1). Multiple stepwise regressions,
which used HU as a dependent variable and significant
HRQoL predictors (domains with p < 0.05) from the
screening step plus baseline characteristics (listed in
Table 1) as the independent variables, were then con-
ducted. The significance levels for variables to enter and
exit the models were 0.05 and 0.10, respectively. The
ANOVA and trend tests were conducted to compare
HU scores and HRQoL domains and scores among sub-
groups with 0, 1, 2, and 3 or more fractures.
Results
Patient characteristics
The mean age for the non-EU cohort was 68.0 years, and
mean height, weight and BMI were 159.7 cm, 65.4 kg, and
25.7 kg/cm2, respectively (Table 2). For the EU cohort, the
mean values for age height, weight and BMI were
67.5 years, 160.1 cm, 64.7 kg, and 25.2 kg/cm2, respectively.
BMI was statistically, significantly higher in the non-EU co-
hort versus the EU cohort. Other statistically significant
differences included a higher percentage of smokers and
alcohol users, more years of education, and more with
self-reported, preexisting medical conditions among the
non-EU cohort compared to the EU cohort. The non-EU
cohort reported a higher percentage of participants with 1
or more osteoporotic non-vertebral fractures and a higher
baseline lumbar BMD score, but a lower percentage of
femoral neck BMD t-scores (Table 2).
Table 3 provides baseline OPAQ, NHP and HUI mean
scores for the non-EU cohort, and QualEFFO, NHP, and
EQ-5D scores for the EU cohort. The mean utility scores
were 0.85 for the non-EU cohort (based on the HUI)
and 0.78 for the EU cohort (based on the EQ-5D).
Correlations between HRQoL and HU measures
The HRQoL domains were well correlated with HU
scores, especially for domains related to pain, physical
Table 1 Association between baseline subject characteristics and HU: EU and Non-EU cohorts
Non-EU cohort EU cohort
Baseline characteristic C Baseline characteristic C
Age (years) 0.16 Age 0.34
Alcohol use (Yes) −0.19 Alcohol use (Yes) −1.03
Height (cm) 0.158* Height (cm) 0.247
Weight (kg) −0.115* Weight (kg) −0.385**
Country AU vs. US −4.359* Country BE vs. UK −9.088*
Country CA vs. US −0.570 Country NL vs. UK −2.997
Country NZ vs. US −1.056 Country SE vs. UK −3.684
Smoke (Yes) −5.204* Smoke (Yes) −8.712**
Prevalent vertebral fractures −0.638 Prevalent vertebral fractures −2.245**
Baseline femoral neck BMD (# of SDs <mean for females) −0.885 Baseline femoral neck BMD (# of SDs <mean for females) 2.192
Number of preexisting conditions −0.447*** Number of preexisting conditions −1.434***
Number of ONF −0.549 Number of ONF 0.751
Years postmenopausal −0.095 Years postmenopausal −0.305
Family history of osteoporosis (Yes) −1.004 Family history of osteoporosis (Yes) 4.332
History of hysterectomy (Yes) −0.008 History of hysterectomy (Yes) −4.723*
Married (Yes) −0.118 Married (Yes) 0.587
Years of education 0.347* Years of education 0.370
Baseline LS BMD (# of SDs < mean for females) 0.472 Baseline LS BMD (# of SDs < mean for females) −0.209
Variance explained 0.14 Variance explained 0.20
Abbreviations: AU Australia, BMD Bone mineral density (score), BE Belgium, C Regression coefficient, CA Canada, EU European Union, LS Lumbar spine,
NL Netherlands, Non-EU Non-European Union, NZ New Zealand, ONF Osteoporotic non-vertebral fractures, SD Standard deviation, SE Sweden, UK Great Britain,
US United States.
*p < 0.05, **p < 0.001, ***p < 0.0001.
Table 2 Baseline subject demographic and clinical characteristics
Baseline characteristic Non-EU (n = 694) EU (n = 551) p-value
Mean (SD) Mean (SD)
Age (years) 68.0 (6.9) 67.5 (6.2) 0.1994
Height (cm) 159.7 (6.3) 160.1 (6.6) 0.3001
Weight (kg) 65.4 (11.0) 64.7 (9.9) 0.2467
Body mass index (kg/cm2) 25.7 (4.2) 25.2 (3.6) 0.0370*
Caucasian (n, %) 672 (96.8) 543 (98.5) 0.0619
Smoker (Yes) (n, %) 617 (88.9) 421 (76.4) <0.0001**
Use of alcohol (Yes) (n, %) 556 (80.1) 406 (73.7) 0.0038*
Number of prevalent vertebral fractures (≥1) (n, %) 433 (62.4) 279 (50.6) <0.0001**
Baseline femoral neck BMD (# of SDs <mean for females) −2.3 (.6) −2.2 (.6) 0.0022*
Number of osteoporotic non-vertebral fractures (≥1) (n, %) 366 (52.7) 202 (36.7) <0.0001**
Family history of osteoporosis (Yes) (n, %) 212 (30.5) 157 (28.5) 0.0001**
History of hysterectomy (Yes) (n, %) 186 (26.8) 134 (24.3) 0.3281
Married (Yes) (n, %) 390 (56.2) 314 (57.0) 0.7732
Number of years postmenopause 20.3 (8.7) 19.4 (7.7) 0.0551
Baseline lumbar spine BMD (# of SDs < mean for females) −2.4 (1.2) −2.7 (1.1) 0.0001**
Number of years of education 13.6 (3.1) 10.1 (3.2) <0.0001**
Number of self-reported preexisting conditions 10.9 (5.9) 5.9 (4.3) <0.0001**
Abbreviations: BMD Bone mineral density, EU European Union, Non-EU Non-European Union, SD Standard deviation.
*p < 0.05, **p < 0.0001.
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Table 3 Summary of baseline EQ-5D, QualEFFO, OPAQ,
HUI, and NHP domains/scores: EU cohort and Non-EU
cohorts
Instrument (Cohort) domain N Mean SD Min Max
OPAQ (Non-EU)
Walking/Bending 693 85.42 17.08 7.14 100.00
Standing/Sitting 692 80.16 20.83 0.00 100.00
Dressing/Reaching 691 93.10 14.76 0.00 100.00
Household/Self Care 692 93.16 12.60 31.25 100.00
Transfers 693 90.66 18.32 0.00 100.00
Usual Work 692 92.02 15.87 0.00 100.00
Fear of Falls 692 73.47 19.44 10.00 100.00
Level of Tension 690 67.93 17.38 15.00 100.00
Body Image 693 67.26 24.77 0.00 100.00
Independence 691 83.83 17.19 0.00 100.00
Back Pain 694 73.71 23.69 0.00 100.00
Fatigue 693 62.52 18.75 0.00 100.00
Social Activity 692 40.44 19.40 0.00 100.00
Support, Family and Friends 691 85.49 20.26 0.00 100.00
NHP (Non-EU)
Emotional Reaction 681 5.08 12.57 0.00 100.00
Energy 688 11.55 23.33 0.00 100.00
Physical Mobility 686 9.54 13.42 0.00 67.16
Pain 678 11.88 21.37 0.00 100.00
Sleep 687 19.47 25.06 0.00 100.00
Social Interaction 684 2.73 9.87 0.00 79.87
HUI (Non-EU) Utility Score 694 0.85 0.12 0.22 1.00
QualEFFO (EU)
Pain 541 68.77 27.20 0.00 100.00
Daily Activity 550 91.20 13.83 11.11 100.00
Mobility 550 77.90 19.61 0.00 100.00
General Health 548 58.25 20.92 0.00 100.00
Mental Health 549 74.95 16.84 12.50 100.00
Overall QOL 524 73.42 20.13 2.00 100.00
NHP (EU)
Emotional Reaction 525 10.07 18.58 0.00 100.00
Energy 547 16.64 29.62 0.00 100.00
Physical Mobility 533 14.02 18.47 0.00 100.00
Pain 526 18.93 26.42 0.00 100.00
Sleep 536 24.37 28.63 0.00 100.00
Social Interaction 533 5.38 14.88 0.00 100.00
EQ-5D (EU) Utility Score 551 0.78 0.23 −0.59 1.00
Abbreviations: EU European Union, HUI Health Utility Index, Max Maximum
score, Min Minimum score, NHP Nottingham Health Profile, Non-EU Non-
European Union, OPAQ Osteoporosis Assessment Questionnaire, QOL Quality
of life, QualEFFO EU Foundation of Osteoporosis Quality-of-Life Assessment, SD
Standard deviation.
Scoring: EQ-5D scores: 0 (worst) - 1.0 (best); HUI scores: 0 (worst) - 1.0 (best);
NHP scores: 0 (best) - 100 (worst); OPAQ scores: 0 (worst) - 100 (best),
QualEFFO scores (54-item QualEFFO): 0 (worst) - 100 (best).
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core domains of the EQ-5D and HUI (Table 4). For
OPAQ, 8 domains had correlations with HUI ≥ 0.40:
 4 from the physical function dimension: walking/
bending, standing/sitting, transfers, and usual work;
 2 from the emotional status dimension: fear of falls
and independence; and
 2 from the symptoms dimension: back pain and
fatigue.
The OPAQ domains of social activity and support,
family and friends, both from the social interaction
dimension, had the weakest correlations with HUI
(Table 4). All correlations between NHP and HUI were
negative, with higher utility values indicating less
distress.
All QualEFFO domains had strong correlations (>0.50)
with EQ-5D utility scores (Table 4). For NHP, all correla-
tions with EQ-5D were negative, with higher HU indicating
less distress.
In both the non-EU and EU cohorts, pain, physical
mobility, and energy had correlations >0.40 with HU
(Table 4). In addition, the EU cohort had a corre-
lation >0.40 in the emotional reaction domain.
The associations between disease-targeted HRQoL and
HU (OPAQ vs. HUI and QualEFFO vs. HUI), from a
clinical point of view, were similar to the associations
between generic HRQoL and HU (NHP vs. HUI and
NHP vs. EQ-5D) in both cohorts (Table 4).
Association between baseline patient characteristics and HU
In the non-EU cohort, BMI, country = Australia (vs.
United States), smoke, and number of preexisting condi-
tions were negatively associated with HU, while years of
education were positively associated with HU (Table 1).
In the EU cohort, BMI, country = Belgium (vs. United
Kingdom), smoke, prevalent vertebral fractures, number
of preexisting conditions, and history of hysterectomy
were negatively associated with HU.
In the analyses of association between baseline patient
characteristics and HU, the variability in HU did not
appear to be explained by baseline characteristics, as HU
variability explained by baseline characteristics was only
13% for non-EU and 19% for EU cohorts, respectively
(Table 1).
Stepwise regression to identify independent HRQoL
predictors of HU
In the multiple stepwise regression models, prior to
adjusting for baseline characteristics, where associations
between HU and HRQoL were examined, multiple
HRQoL domains were found to be significantly associ-
ated with HU. A large percentage of the variance in HU
Table 4 Correlations between HRQoL and HU measures: EU and Non-EU cohorts
Non-EU cohort EU cohort
OPAQ vs. HUI NHP vs. HUI QualEFFO vs. EQ-5D NHP vs. EQ-5D
OPAQ domain r NHP Domain r QualEFFO domain r NHP domain r
Walking/Bending 0.524 Emotional reaction −0.393 Pain 0.571 Emotional reaction −0.561
Standing/Sitting 0.490 Energy −0.477 Daily activity 0.713 Energy −0.593
Dressing/Reaching 0.325 Physical mobility −0.506 Mobility 0.657 Physical mobility −0.596
Household/Self care 0.335 Pain −0.578 General health 0.558 Pain −0.650
Transfers 0.416 Sleep −0.386 Mental health 0.540 Sleep −0.335
Usual work 0.400 Social interaction −0.272 Overall QOL 0.515 Social interaction −0.347
Fear of falls 0.456






Support, family and friends 0.093*
Abbreviations: EU European Union, HUI Health Utility Index, NHP Nottingham Health Profile, Non-EU Non-European Union, OPAQ Osteoporosis Assessment Ques-
tionnaire, QOL quality of life, QualEFFO EU Foundation of Osteoporosis Quality-of-Life Assessment, r = Pearson’s correlation coefficient estimate.
Scoring: OPAQ scores: 0 (worst) - 100 (best), HUI scores: 0 (worst) - 1.0 (best), NHP scores: 0 (best) - 100 (worst), EQ-5D scores: 0 (worst) - 1.0 (best). QualEFFO
scores (54-item QualEFFO): 0 (worst) - 100 (best).
*p < 0.05, p < 0.0001 for all other coefficients.
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non-EU cohorts, 5 OPAQ domains (walking/bending,
back pain, level of tension, fear of falls, and fatigue) were
significantly associated with HU, and together they ex-
plained 41% of the variance in HU. All 6 NHP domains
(pain, emotional reaction, physical mobility, sleep, en-
ergy, and social interaction) were significantly associated
with HU, and together they explained 44% of the vari-
ance in HU. For the EU cohort, 4 QualEFFO domains
(daily activity, mental health, pain, and mobility) were
significantly associated with EQ-5D utility scores, andTable 5 Significant HRQoL predictors of HU from stepwise reg
characteristics: EU and Non-EU cohorts
Non-EU Cohort
OPAQ vs. HUI NHP vs. HUI
n = 677 n = 662
OPAQ domain C NHP domain C
Walking/Bending 0.184 Pain −0.188
Back pain 0.097 Emotional reaction −0.104
Level of tension 0.084 Physical mobility −0.139
Fear of falls 0.101 Sleep −0.067
Fatigue 0.077* Energy −0.055*
Social interaction −0.099*
Variance explained 0.41 Variance explained 0.44
Abbreviations: C Regression coefficient, EU European Union, HUI Health Utility Index
OPAQ Osteoporosis Assessment Questionnaire, QualEFFO EU Foundation of Osteopo
Scoring: OPAQ scores: 0 (worst) - 100 (best), HUI scores: 0 (worst) -1.0 (best), NHP sc
(54-item QualEFFO): 0 (worst) - 100 (best).
*p < 0.05, p < 0.0001 for all other coefficients.together they explained 61% of the variance in HU. Four
NHP domains (pain, emotional reaction, physical mobil-
ity, and energy) were significantly associated with EQ-
5D utility scores, and together they explained 53% of the
variance in HU.
Determinants of HU, with adjustment for baseline patient
characteristics
In the final multiple regression model, where HU was the
dependent variable and significant HRQoL domains from
the screening step plus baseline patient characteristicsression model without adjustment for baseline patient
EU Cohort
QualEFFO vs. EQ-5D NHP vs. EQ-5D
n = 538 n = 495
QualEFFO domain C NHP Domain C
Daily activity 0.689 Pain −0.275
Mental health 0.327 Emotional reaction −0.326
Pain 0.158 Physical mobility −0.274
Mobility 0.132* Energy −0.089*
Variance explained 0.61 Variance Explained 0.53
, NHP Nottingham Health Profile, Non-EU Non-European Union,
rosis Quality-of-Life Assessment.
ores: 0 (best) - 100 (worst), EQ-5D scores: 0 (worst) - 1.0 (best), QualEFFO scores
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targeted and generic HRQoL domains were found to be
significantly associated with HU (Table 6). For the non-
EU cohort, 3 OPAQ domains (walking/bending, fear of
falls, and fatigue) and 4 NHP domains (emotional reac-
tion, pain, sleep, and social interaction) were significantly
associated with HU, and together this model explained
48% of the variance in HU. For the EU cohort, 3 Qua-
lEFFO domains (pain, daily activity, and mental health)
and 2 NHP domains (emotional reaction and pain) were
significantly associated with HU, and together this ex-
plained 64% of the variance in HU.
Additional analyses in both cohorts examined the
associations between the number of prevalent fractures
(ie, vertebral and non-vertebral) and disease-targeted
HRQoL scores, domain scores, and HU scores. (Please
see Additional file 1 and Additional file 2 for results.)
These analyses suggested a decrease in both HRQoL and
HU scores, with an increase in the number of vertebral
and non-vertebral fractures. There was a statistically
significant, direct linear relationship between the num-
ber of vertebral fractures (0, 1, 2, 3+) and a reduction in
HRQoL scores for those in the non-EU and EU cohorts,
based on OPAQ, QualEFFO, NHP, and EQ-5D scores.
The OPAQ walking/bending domain scores in the non-
EU cohort, for example, were 87.4, 86.4, 84.8, and 76.8
for 0, 1, 2, and 3+ vertebral fractures (p < 0.001), while
HUI scores in subjects with 0 or 1 vertebral fracture
declined from 0.9 to 0.8 with 2 or 3+ vertebral fractures
(p = 0.006) (see Additional file 1). There were also statis-
tically significant, linear relationships between the non-
vertebral fractures (0, 1, 2, 3+) and reductions in HRQoL
and HU for those in the non-EU and EU cohorts,
although the number of significant domains and strength
of statistical significance was less pronounced for thoseTable 6 Significant HRQoL predictors of HU from stepwise reg
characteristics
Non-EU cohort
Dependent Var = HUI; Independent Vars = OPAQ, NHP, BD
Domain C D
OPAQ Walking/Bending 0.137*** Q
OPAQ fear of falls 0.071** Q
OPAQ fatigue 0.057* Q
NHP emotional reaction −0.096*** N
NHP pain −0.169*** N
NHP sleep −0.056***
NHP social interaction −0.109*
Variance explained 0.48 Va
Abbreviations: BD Baseline demographic (characteristic), C Regression coefficient EU
Non-EU Non-European Union, OPAQ Osteoporosis Assessment Questionnaire, QualE
Scoring: OPAQ scores: 0 (worst) - 100 (best), HUI scores: 0 (worst) - 1.0 (best), NHP s
scores (54-item QualEFFO): 0 (worst) - 100 (best).
*p < 0.05, **p < 0.001, ***p < 0.0001.with non-vertebral fractures than it was for those with
vertebral fractures (see Additional file 2).
Discussion
Baseline data from a subsample of 1,245 women, who
participated in the MORE study, was utilized to examine
the association between HU and HRQoL, as well as
patient characteristics.
Results of this study revealed that there were multiple
HRQoL domains that were significantly correlated with
HU scores. More specifically, disease-targeted and gen-
eric HRQoL domains were found to be well correlated
with HU scores, especially for domains related to pain,
physical function, and emotional and mental health,
which are basic domains of the EQ-5D and HUI utility
scores.
In the multiple stepwise regression models, where as-
sociations between HU and HRQoL were examined,
multiple HRQoL domains were found to be significantly
associated with HU. A large percentage (41% to 61%) of
the variance of HU scores was explained by HRQoL do-
mains. After adjusting for baseline patient characteris-
tics, the proportion of variance in HU scores explained
by HRQoL domains improved slightly to 48% to 64%,
which indicates that baseline patient characteristics were
not major confounding factors, and that both disease-
targeted and generic HRQoL measures were significantly
correlated with HU.
In the final multiple regression models, with HU as
the dependent variable and the significant HRQoL
domains from the screening step plus the significant
baseline patient characteristics included as independent
variables, there were multiple HRQoL domains signifi-
cantly associated with HU. These significant domains,
from both the disease-targeted and generic HRQoLression model with adjustment for baseline patient
EU cohort
Dependent Var = EQ-5D; Independent Vars = QualEFFO, NHP, BD
omain C
ualEFFO pain 0.108**
ualEFFO daily activity 0.644***
ualEFFO mental health 0.141*
HP emotional reaction −0.299***
HP pain −0.154***
riance explained 0.64
, European Union, HUI Health Utility Index, NHP Nottingham Health Profile,
FFO EU Foundation of Osteoporosis Quality-of-Life Assessment, Var variable.
cores: 0 (best) - 100 (worst), EQ-5D scores: 0 (worst) - 1.0 (best), QualEFFO
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major concepts covered in both HU measures, including
pain, physical function, and emotional and mental
health. After adjusting for baseline patient characteris-
tics, both disease-targeted and generic HRQoL measures
remain significantly correlated with utility scores.
In addition, the number of prevalent fractures was
significantly correlated with both HRQoL and HU scores.
Prevalent fractures, particularly the number of vertebral
fractures, appeared to significantly impact both HRQoL
(OPAQ and QualEFFO) scores, as well as HU (HUI and
EQ-5D) scores. As the number of vertebral fractures
increased, HRQoL and HU scores decreased, as measured
by the OPAQ, QualEFFO, HUI, and EQ-5D.
In general, findings were similar between the 2 cohorts,
despite the different utility and disease-targeted HRQoL
measures. The associations between HRQoL and HU
appeared to be stronger in the EU population (as mea-
sured by the QualEFFO and EQ-5D), compared to the
non-EU population. This result could be due to under-
lying unmeasured differences between the 2 populations
or to the different HU and HRQoL instruments used.
While it is difficult to compare the findings between
the non-EU and EU cohorts directly, given that 2 differ-
ent utility measures were used (HUI and EQ-5D), other
researchers have shown the correlation between EQ-5D
and HUI to be high, 0.71 and 0.67, respectively [26,27].
Characterizing the associations between the OPAQ and
HUI; the QualEFFO and EQ-5D; and the OPAQ,
QualEFFO, and NHP have been original contributions
to the field.
Our results for the non-EU cohort were similar to
those reported by Marciniak et al. [19]. In particular, the
EQ-5D HU scores were similar between studies, as
Marciniak et al. reported a median EQ-5D HU score of
0.796, while our mean study population’s EQ-5D score
was 0.78. The 2 study populations also had similar mini-
mum and maximum EQ-5D score ranges, which repre-
sent substantial variation—the minimum EQ-5D score
reported in both studies was −0.59 (representing health
states worse than death) while the maximum EQ-5D
score reported in both studies was 1.0 (representing
optimal health) [19].
A major strength of our study was that we examined 2
large cohorts of heterogeneous PMO women who repre-
sent non-EU and EU countries, and we were able to
compare 2 parallel sets of instruments that measure
HRQoL and HU. This research has been precedent-
setting. Another strength of this study was that we were
able to measure the impact of important patient baseline
characteristics, such as prevalent fractures, on the
variability of HU and HRQoL scores. Our research is
consistent with prior research on the effects of prevalent
and incident vertebral and non-vertebral fractures onHRQoL and HU scores in separate and distinct popula-
tions [7,8,10-12].
There are important limitations to our study that
warrant further discussion. First, we examined baseline
data only; therefore, we did not compare correlations
over time nor did we attempt to explain changes in
health utility scores over time. Second, the results were
based on a sample of patients from specific countries
within the EU and from English-speaking countries out-
side the EU. The HUI results from the non-EU cohort,
for instance, were substantially weighted by responses
from the US patients given its large proportion of this
cohort. Therefore, caution should be exercised when
attempting to generalize these results to other patient
populations.
Despite these limitations, the results of this study
provide an important contribution toward characterizing
the associations between disease-targeted, generic HRQoL/
health status instruments and preference-based HU mea-
sures in PMO women. In addition, the study demonstrates
that the number of vertebral and non-vertebral fractures
is well correlated with HRQoL and HU scores. The
OPAQ, QualEFFO, EQ-5D, HUI and, to a lesser degree,
NHP scores increased or decreased significantly and in
direct and linear proportion to the number of vertebral
and non-vertebral fractures.
Conclusions
Self-reported HRQoL and HU scores among post-
menopausal women were substantially impacted by
the number of prevalent vertebral fractures and, to a
lesser but still significant degree, non-vertebral frac-
tures. Our study found relatively strong correlations
between multiple disease-specific HRQoL and HU
instruments. A better understanding of how disease-
specific HRQoL and HU measures are related may
help to guide and inform proper instrument selection
for randomized clinical trials and to provide data to
develop more sensitive patient-reported outcomes in-
struments for the osteoporosis population and key
subgroups of interest.Additional files
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